Basilea Pharmaceutica Ag Stock Probability of Future Pink Sheet Price Finishing Under 51.26
| BPMUF Stock | USD 52.83 0.00 0.00% |
Basilea |
Basilea Pharmaceutica Target Price Odds to finish below 51.26
The tendency of Basilea Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 51.26 or more in 90 days |
| 52.83 | 90 days | 51.26 | about 14.28 |
Based on a normal probability distribution, the odds of Basilea Pharmaceutica to drop to $ 51.26 or more in 90 days from now is about 14.28 (This Basilea Pharmaceutica AG probability density function shows the probability of Basilea Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Basilea Pharmaceutica price to stay between $ 51.26 and its current price of $52.83 at the end of the 90-day period is about 67.88 .
Assuming the 90 days horizon Basilea Pharmaceutica AG has a beta of -0.0702 suggesting as returns on the benchmark increase, returns on holding Basilea Pharmaceutica are expected to decrease at a much lower rate. During a bear market, however, Basilea Pharmaceutica AG is likely to outperform the market. Additionally Basilea Pharmaceutica AG has an alpha of 0.0437, implying that it can generate a 0.0437 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Basilea Pharmaceutica Price Density |
| Price |
Predictive Modules for Basilea Pharmaceutica
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Basilea Pharmaceutica. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Basilea Pharmaceutica's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Basilea Pharmaceutica Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Basilea Pharmaceutica is not an exception. The market had few large corrections towards the Basilea Pharmaceutica's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Basilea Pharmaceutica AG, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Basilea Pharmaceutica within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.04 | |
β | Beta against Dow Jones | -0.07 | |
σ | Overall volatility | 0.79 | |
Ir | Information ratio | -0.18 |
Basilea Pharmaceutica Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Basilea Pharmaceutica for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Basilea Pharmaceutica can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| The company reported the revenue of 148.12 M. Net Loss for the year was (6.83 M) with profit before overhead, payroll, taxes, and interest of 30.89 M. | |
| Basilea Pharmaceutica AG has accumulated about 140.74 M in cash with (32.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.89. |
Basilea Pharmaceutica Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Basilea Pink Sheet often depends not only on the future outlook of the current and potential Basilea Pharmaceutica's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Basilea Pharmaceutica's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 11.8 M | |
| Short Long Term Debt | 123.5 M |
Basilea Pharmaceutica Technical Analysis
Basilea Pharmaceutica's future price can be derived by breaking down and analyzing its technical indicators over time. Basilea Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Basilea Pharmaceutica AG. In general, you should focus on analyzing Basilea Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Basilea Pharmaceutica Predictive Forecast Models
Basilea Pharmaceutica's time-series forecasting models is one of many Basilea Pharmaceutica's pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Basilea Pharmaceutica's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Basilea Pharmaceutica
Checking the ongoing alerts about Basilea Pharmaceutica for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Basilea Pharmaceutica help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| The company reported the revenue of 148.12 M. Net Loss for the year was (6.83 M) with profit before overhead, payroll, taxes, and interest of 30.89 M. | |
| Basilea Pharmaceutica AG has accumulated about 140.74 M in cash with (32.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.89. |
Other Information on Investing in Basilea Pink Sheet
Basilea Pharmaceutica financial ratios help investors to determine whether Basilea Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Basilea with respect to the benefits of owning Basilea Pharmaceutica security.